secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2022-08-12T23:59:59+00:00
Accession:  0001104659-22-089676
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics reports Q2 net loss $17M, cash $90.9M; director Bertagnolli resigns for NCI role
--------------------------------------------------------------------------------

- Net loss $17.0M in Q2 2022 ($9.5M in Q2 2021); R&D expenses $14.0M vs $7.2M, driven by manufacturing and trial costs.
- Cash and equivalents $90.9M at June 30, 2022, providing expected runway into mid-2024.
- Initiated Part C of DisTinGuish study (DKN-01 + tislelizumab + chemo) in first-line G/GEJ cancer; also started DeFiance study in second-line CRC.
- Director Dr. Monica Bertagnolli resigned effective Aug 12, 2022 to become Director of the National Cancer Institute; no disagreement with company.
- Presented initial prostate cancer data at ASCO 2022: in combination cohort, all 6 patients had >50% PSA reduction, 5 with measurable disease had partial response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/0001104659-22-089676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/tm2223284d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-089676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer